Elicio Therapeutics, Inc. ELTX
1.52 USD -0.07 (-4.40%)
At closeNov 4, 2026, 4:00 AM EST
1.50 -0.02 -1.32%
Pre-market · Nov 4, 4:00 AM ET
1.45 Day range 1.73
1.44 52-week range 16.00
- YTD
- -80.90%
- 1 year
- -83.57%
- Market cap
- 41.18M
- EPS (ttm)
- -2.16
- Shares out
- 10.79M
- Forward P/E
- -1.96
- YTD return
- -80.90%
- 1-year return
- -83.57%
- Volume
- 516.88K
- Avg volume
- 310.40K
- Open
- 1.71
- Previous close
- 1.59
- Day's range
- 1.45 – 1.73
- 52-week range
- 1.44 – 16.00
- Analysts
- Buy
- Price target
- 9.50 (+525.0%)
- Earnings date
- Aug 13, 2024
2Y -3.11 (-67.46%)
Key statistics
- Enterprise value
- 61.64M
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 4.25
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 0.00%
- Free cash flow
- -22.08M
- Total cash
- 3.42M
- Total debt
- 6.42M
- Return on equity
- -353.02%
- Short % of float
- 0.49%
- 50-day average
- 4.92
- 200-day average
- 5.97
Analyst view
Consensus: buy
Buy
Price target (mean) 9.50 +525.0% upside
Now 1.52
- Target (low)
- 9.00
- Target (mean)
- 9.50
- Target (high)
- 10.00
Ratings (0m) 3 2 buy · 1 hold · 0 sell
- Strong buy1
- Buy1
- Hold1
- Sell0
- Strong sell0
Next earnings
Aug 13, 2024
Expected Aug 13, 2024. Consensus EPS estimate -0.88.
Financials — quick view
ELTX Revenue — quarterly 0
ELTX Net income — quarterly -8.22M
ELTX EPS — quarterly -0.43
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 13, 2024 | Sep 1, 2024 | -0.81 | -1.39 | -0.58 | -71.60% |
| Aug 13, 2024 | Jun 1, 2024 | -0.96 | -0.64 | +0.32 | +33.33% |
| Aug 13, 2024 | Jun 1, 2024 | -0.96 | — | — | — |
| May 15, 2024 | Mar 1, 2024 | -1.09 | — | — | — |
| May 15, 2024 | Mar 1, 2024 | -1.09 | -1.15 | -0.06 | -5.50% |
| Mar 29, 2024 | Dec 1, 2023 | -0.79 | — | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 31, 2024 | Jones Trading | init | — | Buy |
| Aug 23, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Jun 6, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| May 22, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| May 1, 2024 | HC Wainwright & Co. | main | Buy | Buy |
| Apr 1, 2024 | Oppenheimer | reit | Perform | Perform |
About Elicio Therapeutics, Inc.
Elicio Therapeutics, Inc., a clinical-stage biotechnology company, develops a pipeline of novel immunotherapies for the treatment of cancer. Its lead product candidate is ELI-002, a multivalent lymph nodetargeted AMP peptide vaccine that is in Phase II clinical trial to target seven Kirsten rat sarcoma viral oncogene homolog driver mutations. The company is also developing ELI-007, a multivalent lymph nodetargeted AMP peptide vaccine to target mutant v-raf murine sarcoma viral oncogene homolog B1 gene mutations found in solid tumors; and ELI-008, a multivalent lymph nodetargeted AMP peptide vaccine to target p53 hotspot mutations. The company is headquartered in Boston, Massachusetts.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- elicio.com
News
Elicio Therapeutics To Demonstrate Data Of Two Poster Presentations For Its Phase 2 AMPLIFY-7P Trial Of Camupepimut , Expanded Antigen-Agnostic Intratumoral Application Of AMP-Adjuvant Platform At Society For Immunotherapy Of Cancer's Annual Meeting 
Elicio Therapeutics to Present Phase 2 AMPLIFY-7P Results at the SITC 2026 Annual Meeting 
Elicio Therapeutics Presents Late-Breaking Phase 2 AMPLIFY-7P Results At ESMO Congress 2026; Multiple Pre-Specified Subgroup Analyses Favored Camupepimut, Including Patients With And Without Detectable Baseline ctDNA; Encouraging Disease-Free Survival Outcomes Were Observed In Both ctDNA-Negative And ctDNA-Positive Patients 
Elicio Therapeutics Presents Data From Its Phase 2 AMPLIFY-7P Trial Of Camupepimut At European Society For Medical Oncology Congress 2026 
12 Health Care Stocks Moving In Thursday's After-Market Session
Your note
Sign in to keep a note on ELTX — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| CHUDNOVSKY YEKATERINA | Director and Beneficial Owner of more than 10% of a Class of Security | Purchase | Dec 21, 2023 | 0 |
| DEMUTH PETER | Officer | Conversion of Exercise of derivative security | Dec 15, 2024 | 381 |
| VENKATESAN JAY R | Director | Conversion of Exercise of derivative security | Nov 25, 2024 | 180,534 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Group Inc | 2.27% | 245,262 | 1.23M | Sep 29, 2024 |
| Geode Capital Management, LLC | 0.66% | 71,574 | 360.02K | Sep 29, 2024 |
| CM Management, LLC | 0.46% | 50,000 | 251.50K | Sep 29, 2024 |
| Northern Trust Corporation | 0.29% | 30,769 | 154.77K | Sep 29, 2024 |
| State Street Corporation | 0.20% | 21,900 | 110.16K | Sep 29, 2024 |
| Blackrock Inc. | 0.18% | 19,693 | 99.06K | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 1.89% | 203,476 | 1.02M | Sep 29, 2024 |
| Vanguard Extended Market Index Fund | 0.38% | 41,473 | 208.61K | Sep 29, 2024 |
| Fidelity Extended Market Index Fund | 0.32% | 34,422 | 173.14K | Oct 30, 2024 |
| iShares Micro Cap ETF | 0.16% | 17,078 | 85.90K | Oct 30, 2024 |
| Northern Small Cap Core Fund | 0.12% | 13,000 | 65.39K | Sep 29, 2024 |
| Bridgeway Funds Inc-Ultra Small Company Market Fund | 0.12% | 12,500 | 62.88K | Sep 29, 2024 |